DK1207904T3 - Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi - Google Patents

Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi

Info

Publication number
DK1207904T3
DK1207904T3 DK00959150T DK00959150T DK1207904T3 DK 1207904 T3 DK1207904 T3 DK 1207904T3 DK 00959150 T DK00959150 T DK 00959150T DK 00959150 T DK00959150 T DK 00959150T DK 1207904 T3 DK1207904 T3 DK 1207904T3
Authority
DK
Denmark
Prior art keywords
clinical parameters
radioimmunotherapy
new clinical
haematological toxicity
toxicity prior
Prior art date
Application number
DK00959150T
Other languages
Danish (da)
English (en)
Inventor
William Rastetter
Christine White
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1207904T3 publication Critical patent/DK1207904T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Ecology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK00959150T 1999-08-11 2000-07-31 Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi DK1207904T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828899P 1999-08-11 1999-08-11
US09/625,856 US6451284B1 (en) 1999-08-11 2000-07-26 Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
PCT/US2000/020733 WO2001010461A1 (en) 1999-08-11 2000-07-31 New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Publications (1)

Publication Number Publication Date
DK1207904T3 true DK1207904T3 (da) 2008-07-07

Family

ID=26845721

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00959150T DK1207904T3 (da) 1999-08-11 2000-07-31 Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi

Country Status (17)

Country Link
US (3) US6451284B1 (es)
EP (1) EP1207904B1 (es)
JP (1) JP4662672B2 (es)
CN (2) CN1596985A (es)
AT (1) ATE387915T1 (es)
AU (2) AU780222B2 (es)
CA (1) CA2378584C (es)
CY (1) CY1108118T1 (es)
DE (1) DE60038239T2 (es)
DK (1) DK1207904T3 (es)
ES (1) ES2302698T3 (es)
MX (1) MXPA02001403A (es)
MY (1) MY135734A (es)
NO (1) NO329592B1 (es)
PT (1) PT1207904E (es)
TW (1) TWI317284B (es)
WO (1) WO2001010461A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176981B1 (en) 1999-05-07 2005-11-30 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
JP2003513012A (ja) * 1999-08-11 2003-04-08 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
JP2004512262A (ja) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002250352C1 (en) * 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
AU2004251679C1 (en) 2003-06-05 2009-05-28 Genentech, Inc. Combination therapy for B cell disorders
CN102373214B (zh) 2003-11-05 2014-07-09 罗氏格黎卡特股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
EP1755646A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Vascular targets for detecting, imaging and treating neoplasia or neovasculature
MXPA06014069A (es) 2004-06-04 2007-04-25 Genentech Inc Metodo para tratar esclerosis multiple.
AU2006272597A1 (en) 2005-07-25 2007-02-01 Emergent Product Development Seattle Llc Single dose use of CD20-specific binding molecules
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
EP4335863A2 (en) 2007-07-09 2024-03-13 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MY186219A (en) 2009-08-11 2021-06-30 Genentech Inc Production of proteins in glutamine-free cell culture media
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
CA2970734C (en) * 2013-12-17 2019-09-24 Alentic Microscience Inc. Dosimeters including lensless imaging systems
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
AR106230A1 (es) 2015-10-02 2017-12-27 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3714937A1 (en) * 2019-03-28 2020-09-30 Koninklijke Philips N.V. Determining hematologic toxicity risk following radiotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
EP0556285A4 (en) 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL114909A (en) * 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5843436A (en) * 1996-04-22 1998-12-01 The Trustees Of Columbia University, In The City Of New York Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1176981B1 (en) 1999-05-07 2005-11-30 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
CA2375912C (en) 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Also Published As

Publication number Publication date
US7195750B2 (en) 2007-03-27
EP1207904A1 (en) 2002-05-29
NO329592B1 (no) 2010-11-22
JP4662672B2 (ja) 2011-03-30
ES2302698T3 (es) 2008-08-01
CA2378584C (en) 2011-10-11
NO20020637D0 (no) 2002-02-08
AU780222B2 (en) 2005-03-10
PT1207904E (pt) 2008-06-17
US6451284B1 (en) 2002-09-17
DE60038239T2 (de) 2009-04-30
US20070148714A1 (en) 2007-06-28
WO2001010461A1 (en) 2001-02-15
ATE387915T1 (de) 2008-03-15
US20030211038A1 (en) 2003-11-13
DE60038239D1 (de) 2008-04-17
AU2005202560A1 (en) 2005-07-07
CN1450911A (zh) 2003-10-22
CA2378584A1 (en) 2001-02-15
CN1596985A (zh) 2005-03-23
CN100540053C (zh) 2009-09-16
AU7052100A (en) 2001-03-05
JP2003506414A (ja) 2003-02-18
NO20020637L (no) 2002-04-11
TWI317284B (en) 2009-11-21
EP1207904A4 (en) 2002-10-25
MXPA02001403A (es) 2002-08-12
AU2005202560B2 (en) 2008-01-31
MY135734A (en) 2008-06-30
CY1108118T1 (el) 2014-02-12
EP1207904B1 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
DK1207904T3 (da) Nye kliniske parametre til bestemmelse af hæmatologisk toksicitet forud for radioimmunterapi
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
DK1404377T3 (da) Forbedrede chelatorkonjugater
BRPI0620436B8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
EA200101046A1 (ru) Производные индигоидных бис-индолов
GB0031527D0 (en) New use
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
ID24876A (id) Senyawa-senyawa indola tersubstitusi-2,3 sebagai penghambat cox-2
PT1222159E (pt) Intermediarios de fabricacao de um derivado de tipo benzofurano ou benzotiofeno nitrado em posicao 5 e as suas utilizacoes
BR0312863A (pt) Derivados de aldeìdo de polietileno glicol
EA200100854A1 (ru) Кальций-литические соединения
BR9913389B1 (pt) agentes de preparaÇço, bem como precesso para sua preparaÇço.
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
RS20060195A (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
PT1244614E (pt) Inibidores de triptase
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
ID27733A (id) Metoksiminofenilasetamida
EA200200160A1 (ru) Аналоги псевдомицина с n-ацильной боковой цепью
DK1064265T3 (da) Syntese af 3-amino-2-chlor-4-methylenpyridin fra malononitril og acetone
FR2842109B1 (fr) Utilisation d'un extrait de chrysanthellum
ITRM20010309A0 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
IT1320082B1 (it) Procedimento per la realizzazione di reggiseni, nonche' reggisenocosi' ottenuto.